The size of the In-vitro toxicology testing market in Europe is expected to reach USD 12128.43 Million by 2026 from USD 6597.41 Million in 2021, growing at a CAGR of 12.95% during the forecast period.
In-vitro toxicology testing is the scientific analysis of toxic effects produced by chemical substances on cultured mammalian cells or bacteria. Toxicity testing is essential in drug discovery as it identifies the poisonous effects of a new compound in the early stages of drug discovery. This early detection of toxicity reduces the development cost and time.
Increasing chronic diseases, growing aging population, rising technological advancements, growing demand for a healthy lifestyle, availability of government-supported anti-animal testing laws, and the existence of favorable regulatory policies (such as European government banned the production & sale of all animal-tested cosmetics in Europe) are driving the growth of in-vitro toxicology testing market in Europe. However, the high cost of technologies and lack of awareness on the in-vitro toxicology testing utilization are restraining the growth of the in-vitro toxicology testing market in Europe.
This research report segmented and sub-segmented into the following categories:
Based on product type, the Assays segment is estimated to command the largest share of Europe in-vitro toxicology testing market by product in 2019. Systemic toxicity is assessed to control Europe's largest share in-vitro toxicology testing market by toxicity endpoints & tests in 2019. Technology is further segmented as OMICS technologies & cell culture technology.
Based on Method, the In-silico method is estimated to command the largest share of Europe in-vitro toxicology testing market by the method in 2016. The cosmetics & household products industry is expected to account for the largest market share of Europe in-vitro toxicology testing market by industry in 2019.
Based on the region, Germany is estimated to account for the largest share of the Europe in-vitro toxicology testing market in 2019. In contrast, France is expected to grow at the highest CAGR during the forecast period.
Companies dominating European In-Vitro Toxicology Market profiled in this report are Covance, Inc. (A subsidiary of LabCorp) (U.S.), Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Eurofins Scientific SE (Luxembourg), General Electric Company (U.S.), BioReliance, Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Catalent (U.S.) and Cyprotex (U.K.).
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Assays
5.1.3 Reagents & Labware
5.1.4 Services Growth Hormone Therapy
5.2 Type
5.2.1 Introduction
5.2.2 ADME (Absorption, Distribution, Metabolism, and Excretion)
5.2.3 Dose
5.2.4 Toxic Substance
5.3 Toxicity Endpoints & Tests
5.3.1 Introduction
5.3.2 Systemic Toxicity
5.3.3 Dermal Toxicity
5.3.4 Carcinogenicity
5.3.5 Ocular Toxicity
5.3.6 Skin Sensitization & Irritation
5.3.7 Genotoxicity
5.3.8 Neurotoxicity
5.3.9 Organ Toxicity
5.3.10 Other Toxicity Endpoints & Tests
5.4 Technology
5.4.1 Introduction
5.4.2 OMICS Technologies
5.4.3 Cell Culture Technology
5.4.4 High-Throughput Technologies
5.4.5 Molecular Imaging Technologies
5.5 Method
5.5.1 Introduction
5.5.2 In-Silico Methods
5.5.3 Biochemical Assays
5.5.4 Cellular Assays
5.5.5 Ex-Vivo Models
5.6 Industry
5.6.1 Introduction
5.6.2 Cosmetics and Household Products
5.6.3 Diagnostics
5.6.4 Pharmaceuticals
5.6.5 Food Industry
5.6.6 Chemicals
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Covance, Inc. (A subsidiary of LabCorp) (U.S.)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Agilent Technologies, Inc. (U.S.)
8.3 Bio-Rad Laboratories, Inc. (U.S.)
8.4 Eurofins Scientific SE (Luxembourg)
8.5 General Electric Company (U.S.)
8.6 BioReliance, Inc. (U.S.)
8.7 Charles River Laboratories International, Inc. (U.S.)
8.8 Thermo Fisher Scientific, Inc. (U.S.)
8.9 Catalent (U.S.)
8.10 Cyprotex (U.K.)
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
